Analyze Diet

Double-blinded placebo-controlled clinical field trial to evaluate the safety and efficacy of topically applied 1% diclofenac liposomal cream for the relief of lameness in horses.

Abstract: A topical 1% diclofenac liposomal cream proved to be safe, easy to use, and effective in reducing equine lameness caused by degenerative joint disease. Diclofenac liposomal cream was shown to reduce lameness as graded by owners and veterinarians, regardless of the severity or chronicity of the clinical condition. Topical application allowed for more convenient administration than oral or injectable agents, and no clinically relevant hematologic or serum biochemical changes were noted. The liposomal cream provided a delivery system for diclofenac, an NSAID, to achieve therapeutic levels locally with decreased risk for systemic toxicity and side effects and improved targeting of the painful area.
Publication Date: 2004-10-07 PubMed ID: 15468010
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
  • Clinical Trial
  • Journal Article
  • Randomized Controlled Trial
  • Research Support
  • Non-U.S. Gov't

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This study investigates the effect of a topical 1% diclofenac liposomal cream on alleviating lameness in horses, confirming it as safe, user-friendly, and successful in combating disability due to degenerative joint disease.

Overview of the Research

  • The research conducted a double-blinded placebo-controlled clinical field trial to evaluate the safety and efficacy of topically applied 1% diclofenac liposomal cream on lame horses.
  • The horses suffered from various degrees of lameness attributed to degenerative joint disease; a common chronic condition in horses that results in pain and reduced mobility.

Efficacy of Diclofenac Liposomal Cream

  • The study found that the use of Diclofenac Liposomal Cream successfully reduced lameness in horses, as reported both by owners and veterinarians, regardless of the severity or chronicity of the clinical condition. This implies that the drug was effective across different stages and severities of the disease.
  • The method of application was also beneficial as a topical application is often easier and more convenient than oral or injectable methods. This increases the likelihood of consistent and proper usage.

Safety of Diclofenac Liposomal Cream

  • The cream did not cause any clinically significant changes in hematological or serum biochemical levels, affirming its safety for use in horses.
  • Diclofenac Liposomal Cream provides a delivery system for Diclofenac, a non-steroidal anti-inflammatory drug (NSAID). This helps achieve therapeutic levels locally, minimizing systemic toxicity and side effects. This means it is more targeted and less likely to affect other body systems or cause undesired reactions.

Significance of the Findings

  • This research is significant as it proposes a safe, effective, and convenient therapeutic option for managing lameness in horses due to degenerative joint disease. It can drastically improve the quality of life for these animals.
  • Furthermore, the study also provides an instance where topical application can be just as or even more beneficial than traditional oral or injectable forms, broadening the scope and potential applications of drug delivery systems.

Cite This Article

APA
Lynn RC, Hepler DI, Kelch WJ, Bertone JJ, Smith BL, Vatistas NJ. (2004). Double-blinded placebo-controlled clinical field trial to evaluate the safety and efficacy of topically applied 1% diclofenac liposomal cream for the relief of lameness in horses. Vet Ther, 5(2), 128-138.

Publication

ISSN: 1528-3593
NlmUniqueID: 100936368
Country: United States
Language: English
Volume: 5
Issue: 2
Pages: 128-138

Researcher Affiliations

Lynn, Randy C
  • IDEXX Pharmaceuticals Inc, Greensboro, NC, USA.
Hepler, Douglas I
    Kelch, William J
      Bertone, Joseph J
        Smith, Barbara L
          Vatistas, Nicholas J

            MeSH Terms

            • Administration, Topical
            • Animals
            • Anti-Inflammatory Agents, Non-Steroidal / administration & dosage
            • Anti-Inflammatory Agents, Non-Steroidal / adverse effects
            • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
            • Diclofenac / administration & dosage
            • Diclofenac / adverse effects
            • Diclofenac / therapeutic use
            • Double-Blind Method
            • Female
            • Horse Diseases / drug therapy
            • Horses
            • Joint Diseases / drug therapy
            • Joint Diseases / veterinary
            • Lameness, Animal / drug therapy
            • Liposomes
            • Male
            • Placebos
            • Safety
            • Severity of Illness Index
            • Treatment Outcome

            Citations

            This article has been cited 1 times.
            1. Kayasuga-Kariya Y, Iwanaga S, Fujisawa A, Lin LS, Suzuki S, Chung UI, Sasaki N, Shimohata N, Mochizuki M. Dermal cell damage induced by topical application of non-steroidal anti-inflammatory drugs is suppressed by trehalose co-lyophilization in ex vivo analysis. J Vet Med Sci 2013 Dec 30;75(12):1619-22.
              doi: 10.1292/jvms.12-0502pubmed: 23884023google scholar: lookup